Evidence map›Paper›PMID 38171876›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Anti-IgLON5 Disease Showing an Improvement in Dysautonomia, Including Vocal Cord Palsy, via Combined Immunotherapy.

Daisuke Sato, Hiroyasu Sato, Toshiyuki Kondo, Ryosuke Igari, Chifumi Iseki, Hikaru Kawahara, Shintaro Amano, Yoya Ono, Akio Kimura, Takayoshi Shimohata and 1 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daisuke SatoDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Hiroyasu SatoDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Toshiyuki KondoDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Ryosuke IgariDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Chifumi IsekiDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Hikaru KawaharaDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.
Shintaro AmanoDepartment of Otolaryngology, Head and Neck Surgery, Yamagata University School of Medicine, Japan.
Yoya OnoDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.
Akio KimuraDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.
Takayoshi ShimohataDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.
Yasuyuki OhtaDivision of Neurology and Clinical Neuroscience, Department of Internal Medicine III, Yamagata University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-IgLON5 disease shows various neurological manifestations, of which dysautonomia is one of the major symptoms and is rarely improved by immunotherapy. We herein report a patient with anti-IgLON5 disease who showed several autonomic failures, including vocal cord palsy for four months. The patient presented with cognitive impairments, bulbar symptoms accompanied by myorhythmia in the pharynx and tongue, cerebellar ataxia with tremor, motor neuron symptoms in the limbs, gastrointestinal dysfunction, orthostatic hypotension, non-rapid eye movement sleep disorder on polysomnography, and severe vocal cord palsy. Combined immunotherapy improved his symptoms, including vocal cord palsy, suggesting that combined immunotherapy might improve dysautonomia in anti-IgLON5 disease.

Indexed as

ImmunotherapyPrimary DysautonomiasVocal Cord ParalysisAutoantibodiesCell Adhesion Molecules, NeuronalHumansMaleMiddle AgedTreatment OutcomeAutoantibodiesCell Adhesion Molecules, NeuronalIgLON5 protein, humananti-IgLON5 diseasecombined immunotherapydysautonomiavocal cord palsy

Identifiers

PMID38171876
PMCPMC11358744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.